E-mail Print PDF

During the course of a normal day, humans breathe nearly 25,000 times. Respiratory diseases range from mild and self-limiting such as the common cold to life-threatening such as bacterial pneumonia or pulmonary embolism.

They are a common and prevalent cause of illness and death that affect millions of people worldwide. If all types of lung disease are lumped together, it is the number three killer in the United States. Our Respiratory group is a dedicated clinical operations team with years of experience working on global trials across this diverse spectrum of indications in both adult and pediatric populations.

With our therapeutic and regulatory expertise, we can provide strategic thinking and full clinical plan development that considers the scientific rigor of a specific program. We deploy specialized recruitment and retention strategies that have proven success in respiratory trials. Our monitoring, project management and data management team members have conducted more than 48 Phase I-IV respiratory trials across multiple indications. These include:



Cystic fibrosis

Lower respiratory tract infections

Lung cancer

Pulmonary arterial hypertension

Smoking cessation

Upper respiratory tract infections

For more information on Andronovo’s therapeutic expertise in Respiratory, click here.

You are here: Therapeutic Expertise Respiratory

Contact Us

For a quick business enquiry, feel free to contact us.